<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04223739</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A00763-54</org_study_id>
    <nct_id>NCT04223739</nct_id>
  </id_info>
  <brief_title>Comparison of Two Strategies for the Management of Atrial Fibrillation After Cardiac Surgery</brief_title>
  <acronym>FAAC</acronym>
  <official_title>Comparison of Two Strategies for the Management of Atrial Fibrillation After Cardiac Surgery : a Randomized Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative atrial fibrillation is a common complication after cardiac surgery with a rate
      of 30%. However, management of postoperative atrial fibrillation is controversial. Two
      strategies are recommended : heart rate control using a betablocker or rhythm control with
      amiodarone.

      Landiolol is a new-generation beta-blocker with a short half-life, which was approved by the
      Haute Autorité de Santé to be used in perioperative supra-ventricular tachycardias.

      Only one study compared landiolol to amiodarone in the perioperative setting, with a better
      hemodynamic tolerance and a higher rate of conversion to sinus rhythm with landiolol. However
      this was a single-center and retrospective study.

      The aim of our multicenter randomized study is to compare the effectiveness of landiolol in
      reducing atrial fibrillation to sinus rhythm compared to amiodarone in the postoperative
      period after cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized clinical study comparing landiolol and amiodarone for treatment of atrial
      fibrillation following cardiac surgery
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients in sinus rhythm 48 hours after the onset of atrial fibrillation immediate postoperative period after cardiac surgery</measure>
    <time_frame>Day 2 after onset of atrial fibrillation</time_frame>
    <description>Percentage of patients in sinus rhythm 48 hours after the onset of atrial fibrillation immediate postoperative period after cardiac surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haemodynamic side effects (hypotension, bradycardia)</measure>
    <time_frame>Day 8 after onset of atrial fibrillation and through hospital discharge, an average of 14 days</time_frame>
    <description>Haemodynamic side effects (hypotension, bradycardia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Day 8 after onset of atrial fibrillation and through hospital discharge, an average of 14 days</time_frame>
    <description>Length of stay in the hospital from randomisation to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of thrombo-embolic events</measure>
    <time_frame>2 months postsugery and 1 year postsurgery</time_frame>
    <description>Rate of stroke or ischemic embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluated by the EQ 5D 3L questionnaire</measure>
    <time_frame>2 months postsurgery and 1 year postsurgery</time_frame>
    <description>Quality of life as evaluated by the EQ 5D 3L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of atrial fibrillation recurrence</measure>
    <time_frame>2 months postsurgery and 1 year postsurgery</time_frame>
    <description>Percentage of patients having a recurrence of atrial fibrillation after the initial conversion to sinus rythm in the postoperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe hemorrhagic complications due to anticoagulant therapy, as defined by the Haute Autorité de Santé</measure>
    <time_frame>2 months postsurgery and 1 year postsurgery</time_frame>
    <description>Hemorrhagic complications requiring surgery or interventional radiology Hemorrhagic complications responsible of hemodynamic instability (Systolic Arterial Pressure &lt; 90 mmHg, or drop of more than 40 mmHg or Mean Arterial Pressure &lt; 65 mmHg or signs of shock) Life threatening hemorrhagic complications (intracerebral, intramedullar or intraocular hemorrhage, hemothorax, abdominal hemorrhage, deep muscular hemorrhage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Landiolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Landiolol infusion starting at 2.5 µg/kg/min and titrating up to 80µg/kg/min with a heart rate goal of under 90 bpm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amiodarone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amiodarone bolus of 5-7 mg/kg in 1 hour, followed by an infusion of 1g/day until conversion to sinus rhythm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Landiolol</intervention_name>
    <description>Landiolol infusion with incremental doses (range from 2,5µg/kg/min to 80 µg/kg/min) with go of heart rate &lt; 90 bpm. Doses are modified every 10 minutes if necessary.
Once heart rate goal is obtained, switch to an oral dose of Bisoprolol.</description>
    <arm_group_label>Landiolol</arm_group_label>
    <other_name>Rapibloc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Amiodarone loading dose of 5-7 mg/kg in 1 hour followed by an infusion of 1 g/day until conversion to sinus rhythm. Once sinus rhythm is obtained, switch to an oral dose of 200mg/day</description>
    <arm_group_label>Amiodarone</arm_group_label>
    <other_name>Cordarone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients hospitalized in the cardiac ICU after having undergone cardiac surgery
             (CABG, aortic valve or ascending aortic root replacement or a combination of both)

          -  New onset of atrial fibrillation lasting more than 30 minutes in the postoperative
             period after cardiac surgery

          -  French speaking patients

          -  Written consent

          -  Patients with social security insurance

        Exclusion Criteria:

          -  Hemodynamic instability requiring electrical cardioversion of atrial fibrillation

          -  Sepsis

          -  Bradyarrythmia (&lt; 90/min)

          -  Patients requiring inotropes in the postoperative period

          -  Patient with pre-existing atrial fibrillation

          -  Patient with anticoagulant therapy before surgery

          -  Contraindication to amiodarone or beta-blockers

          -  Urgent surgery (&lt; 24h), ventricular assist device, heart transplant, TAVR, mechanical
             valve, mitral or tricuspid valve replacement.

          -  No written consent

          -  Pregnant women,

          -  Underaged patients (&lt;18 years old)

          -  Patients not able to give consent (curators, patients deprived of public rights)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edouard Caspersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edouard Caspersen, MD</last_name>
    <phone>+33 02 31 06 47 36</phone>
    <email>caspersen-e@chu-caen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc-Olivier Fischer, MD-PhD</last_name>
    <phone>+33 02 31 06 47 36</phone>
    <email>fischer-mo@chu-caen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edouard Caspersen, MD</last_name>
      <phone>+33 02 31 06 47 36</phone>
      <email>caspersen-e@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Edouard Caspersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc-Olivier Fischer, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Surgery</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Landiolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

